Search
Cytosorbents Corp
CTSOAdd to Watchlist
0.391USD
+0.017+4.55%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
24.55MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+4.55%
5 Days
-16.27%
1 Month
-16.44%
6 Months
-38.83%
Year to Date
-38.83%
1 Year
-69.69%
Key Figures
0.395Open
0.410High
178.82KVolume
LossP/E TTM
10.35P/E Dynamic
--Dividend TTM
0.28%Turnover Ratio
0.374Prev. Close
0.382Low
63.99KTurnover
LossP/E Static
2.72P/B
0.00%Div Yield TTM
-25.94%ROA
1.39052wk High
0.68Volume Ratio
-20.72MNet Profit
62.79MShares
-0.1891EPS TTM
1.37Beta
-141.59%ROE
0.43552wk Low
7.57%Amplitude
69.16%Gross Margin
24.55MMarket Cap
-4.68Reward/Risk
4.72%Risk Rate
TradingKey Stock Score of Cytosorbents Corp
Currency: USD Updated: 2026-06-30Key Insights
Cytosorbents Corp's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 127 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 2.88.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Cytosorbents Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Cytosorbents Corp Highlights
StrengthsRisks
CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 19.23% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 37.06M.
Overvalued
The company’s latest PE is -1.98, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 16.20M shares, decreasing 5.98% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 1.40K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.98.
Analyst Rating
Based on
1
analysts
Hold
Current Rating
2.875
Target Price
+668.72%
Upside Space
Cytosorbents Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Cytosorbents Corp Info
CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system.
Ticker SymbolCTSO
CompanyCytosorbents Corp
CEOChan (Phillip P)
Websitehttps://cytosorbents.com/
Related Instruments
+2.62%
+2.41%
+1.57%
+1.18%
+1.73%
+1.30%
-0.50%
+1.27%
+7.60%
+0.88%
+0.39%
+0.89%
+1.92%
+1.70%
+3.09%
+2.12%
+1.08%
+1.78%
+0.41%
+0.78%Popular Instruments
FAQs
What is the current price of Cytosorbents Corp (CTSO)?
The current price of Cytosorbents Corp (CTSO) is 0.39.
What is the symbol of Cytosorbents Corp?
The ticker symbol of Cytosorbents Corp is CTSO.
What is the 52-week high of Cytosorbents Corp?
The 52-week high of Cytosorbents Corp is 1.39.
What is the 52-week low of Cytosorbents Corp?
The 52-week low of Cytosorbents Corp is 0.43.
What is the market capitalization of Cytosorbents Corp?
The market capitalization of Cytosorbents Corp is 24.55M.
Is Cytosorbents Corp (CTSO) currently rated as Buy, Hold, or Sell?
According to analysts, Cytosorbents Corp (CTSO) has an overall rating of signal_hold, with a price target of 2.88.
What is the Earnings Per Share (EPS TTM) of Cytosorbents Corp (CTSO)?
The Earnings Per Share (EPS TTM) of Cytosorbents Corp (CTSO) is -0.13.